Race is pleased to announce the appointment of Professor Didier Blaise to the Clinical Advisory Board. Mr Blaise is Professor of Medicine at the Aix-Marseille University in Marseille, France and
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019.
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr Marinella Messina as its Australian Clinical Program Director.